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shere have been many new developments in the broad fields
f epidemiology, health services research (HSR), and out-
omes research during the past year, many more than can be
iscussed in detail in this review. We selected articles
ublished since the last article in this series (1), covering
oughly the period April 2007 through March 2008, that
xamined important issues or advanced research methods in
he field.
pidemiology
he focus of genetic epidemiology studies has shifted from
esting variations in specific candidate genes that encode
roteins suspected of a role in the pathogenesis of athero-
clerosis to testing a comprehensive set of markers spaced
cross the entire genome. This “whole-genome association”
pproach aims to find all the common genetic variants that
re linked to disease, whether or not there is pathophysio-
ogic evidence of their importance. Several large whole-
enome association studies have reported that common
ariants in an interval on chromosome 9 (9p21) are associ-
ted with coronary disease (2–4). These associations have
een replicated in different populations and appear to
redict risk in individuals of either European ancestry or
frican-American ancestry (5). Although a statistical asso-
iation has been shown, the mechanism by which 9p21
enetic variants affects risk remain to be elucidated.
The replication of genetic associations in independent
tudies is important because the screening of multiple
arkers often leads to “false positives.” The importance of
eplication was underscored by a report based on patients
ith acute coronary syndrome from 2 Kansas City hospitals
6) in which only 1 of the 85 genetic variants previously
eported as significant predictors of coronary disease was
eplicated independently. This study also underscores the
onsiderable bias toward publication of “positive studies”
ver “negative studies” in major journals. All well-designed
rom the Departments of *Health Research and Policy and †Medicine, Stanford
niversity School of Medicine, Stanford, California; and the ‡Palo Alto Veterans
ffairs Medical Center, Palo Alto, California. Dr. Heidenreich is a consultant to
iemens Diagnostics.I
Manuscript received October 7, 2008; revised manuscript received January 8, 2009,
ccepted January 19, 2009.tudies attempting to replicate genetic associations should
e reported to dispel overoptimism based on single prom-
sing results.
For genetic markers to be useful, they will have to inform
linical decisions, change patient management, and ultimately
mprove patient outcomes. Few new risk markers have been
ubjected to such rigorous evaluation. Anderson et al. (7)
valuated pharmacogenetic-guided dosing of warfarin in a
andomized trial of 206 patients who had been genotyped for
ariants (CYP 2C9*2, CYP 2C9*3, VKORCI) that had been
reviously shown to affect response to warfarin. One-half of
he patients had warfarin dosing based on a nomogram that
ncluded genotype data, and the other one-half had warfarin
anaged conventionally. Although patients assigned to phar-
acogenetically guided therapy had fewer dose adjustments
ver the 3 months to follow (3.0 vs. 3.6, p 0.05), they spent
o more time in the therapeutic range (69.7% vs. 68.3%, p 
.85), and were no less likely to experience a serious adverse
vent (4.0% vs. 5.1%, p  0.71). This well-designed study
uggests that considerable work remains in translating genetic
arker data into improved clinical management.
isk Assessment
stimation of individual patient risk is a key element in
ecisions about the initiation of drug therapy, and the
ramingham risk score has been extensively evaluated as a
redictor of future cardiovascular events in asymptomatic
ndividuals. D’Agostino et al. (8) used the original Framing-
am Heart Study population and the more recently re-
ruited Framingham Offspring Study population to extend
he risk score to the prediction of any cardiovascular disease
vent, including stroke and peripheral artery disease events
s well as coronary heart disease and heart failure. This
eneral cardiovascular disease risk score had good discrim-
nation (a c-index of 0.76 in men and 0.79 in women), was
ell calibrated, and had significant net reclassification im-
rovement measures.
Although the Framingham risk score is widely used,
oronary disease is still unpredictable, and there is wide-
pread interest in the development of novel risk markers.
mpaired renal function has drawn considerable interest as a
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Year in Epidemiology, HSR, and Outcomes Research April 21, 2009:1459–66otentially overlooked risk factor for coronary disease. Deo
t al. (9) from the Health ABC Study showed that serum
reatinine and cystatin-C predicted cardiac events in a
ohort of 3,044 subjects ages 70 to 79 years at entry, even
fter adjusting statistically for established risk factors.
The development of numerous biomarkers has raised
uestions regarding their incremental value in predicting
eart disease and death. The Uppsala Longitudinal Study of
dult Men reported that a combination of 4 biomarkers
i.e., troponin I, N-terminal pro-hormone brain natriuretic
eptide (NT-proBNP), cystatin C, and high-sensitivity
-reactive protein) improved risk stratification beyond tra-
itional risk cardiovascular risk factors (10), with discrimi-
ation based on the c-statistic improving from 0.66 to 0.77.
imilar findings were observed in a subset of patients
ithout cardiovascular disease at baseline.
Coronary artery calcification (CAC) also has attracted
onsiderable interest as a potential predictor of coronary
rtery disease events in asymptomatic populations. In the
ast year, several large cohort studies reported long-term
utcome data in relation to coronary calcium scores (11–13).
udoff et al. (11) followed 25,253 subjects for an average of
.8 years, during which 510 patients died (2.0%). Unad-
usted 10-year mortality ranged in graded fashion from a
ow of 0.4% in subjects with a CAC score of 0 to a high of
7% in those with a CAC score 1,000, and CAC scores
dded significantly to a prediction model containing stan-
ard risk factors. The MESA (Multi-Ethnic Study of
therosclerosis) also reported that CAC scores improved
he c-index from 0.79 to 0.83 of a predictive model that
ncluded standard risk factors (13). The implications of a
iven CAC score may depend on patient characteristics,
owever, as African-American subjects had a greater
ardiovascular risk at every level of CAC score in studies
y Nasir et al. (12) and the MESA investigators (13).
isk Reduction
he substantial reduction in coronary disease mortality in
he U.S. and Western Europe has been a major accomplish-
ent. But like all successes, there is a question of where the
redit should go; 2 recent studies addressed the cause of this
ecline in population level mortality (14,15). Ford et al. (14)
sed the IMPACT model of coronary heart disease out-
omes to examine the contribution of various factors to the
eduction of coronary deaths in the U.S. between 1980 and
000. They estimate that 47% of the deaths were averted by
reatment for established coronary disease, whereas 44%
ere averted by changes in risk factor levels (Fig. 1).
ardoon et al. (15) estimated that 46% of the decline in
he rate of myocardial infarction (MI) between 1978 and
003 in the British Regional Heart Study could be
ttributed to lower risk factor levels, primarily by a fall in
igarette smoking. rconomic Evaluation
ssessment of the economic impact of new diagnostic and
herapeutic options has become increasingly important as
arge health systems attempt to control rising costs. The
ajor question has been whether the greater costs of new
echnology are justified by much better outcomes.
Ultrasonography for abdominal aortic aneurysm is one of
he few cardiovascular screening tests ever evaluated in a
andomized trial. Seven-year follow-up of the MASS (Mul-
icentre Aneurysm Screening Study) trial of 67,770 patients
16) showed abdominal aortic aneurysm mortality was reduced
7% by screening, whereas costs were increased only $135 per
atient, yielding an attractive cost-effectiveness ratio of $19,500
er life-year added (Fig. 2).
The cost-effectiveness of coronary revascularization com-
ared with medical therapy was assessed in an observational
tudy in the United Kingdom by Griffin et al. (17). Costs
ere increased more by bypass surgery than by angioplasty,
ut bypass surgery was cost-effective among appropriate
andidates as a result of improved quality of life ($40,400
er quality-adjusted life-year [QALY]). By contrast, angio-
lasty has a less favorable cost-effectiveness ratio compared
ith medical therapy, even among appropriate candidates
$86,300 per QALY).
Cardiac resynchronization therapy (CRT) is another
ostly new technology that has been scrutinized for its
ost-effectiveness. A National Institutes of Clinical Effec-
iveness economic model (18) showed that CRT increased
osts by $21,400 per patient, and QALYs by 0.70, yielding
favorable cost-effectiveness ratio ($30,700 per QALY).
dding defibrillation capability to a CRT device increased
osts by another $21,500 but did not increase QALYs in
roportion (0.29) and consequently had a less favorable
ost-effectiveness ratio of $73,800 per QALY.
Heart failure-management programs aim to improve
linical outcomes and reduce long-term costs but require
p-front expenditures. Chan et al. (19) used a Markov
odel to assess the economic impact of heart failure
anagement programs, and found a favorable cost-
ffectiveness ratio of $9,700 per life-year gained, which was
ot affected by variation in model assumptions.
uality Improvement
chieving full use of evidence-based therapies for heart
isease in routine clinical practice has proved to be a
hallenge, so there is great interest in improving systems to
eliver greater quality of care. A clinical trial in the
etherlands randomized 38 general practices that were
sing electronic medical record systems to receive alerts
hen patients needed to be screened or treated for lipid
bnormalities (20). Practices that received alerts were sig-
ificantly more likely to follow guideline recommendations
n screening and treatment than practices that were not
eminded. Heidenreich et al. (21) performed a randomized
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April 21, 2009:1459–66 Year in Epidemiology, HSR, and Outcomes Researchrial of clinical reminders embedded in echocardiography
eports about the use for beta-blockers in patients with a
epressed ejection fraction (40%). Those randomized to the
eminder were significantly more likely to receive a prescription
or a beta-blocker within the next 9 months (74%) compared
ith those not receiving the reminder (64%).
Even if physicians prescribe evidence-based therapies,
atients may not take them. In Ontario 18% of patients
ever filled their cardiac medication prescriptions in the year
fter discharge for an acute MI (22). Patients who filled all
f their prescriptions were younger, had lower income levels,
nd fewer prescriptions before admission, and were more
ikely to have received pre-discharge counseling. Patients
ho filled all their prescriptions also had significantly lower
ortality in the subsequent years. Adherence to guideline-
ased therapy may be improved by active interventions. The
ichigan Guidelines Applied in Practice program (23)
ound that patients treated in hospitals that used an explicit
discharge contract” with patients about cardiac medication
se had better adherence and lower mortality over the
ubsequent year of follow-up.
The initial treatment of ST-segment elevation MI re-
Figure 1 Percentage of Decrease in Deaths From Coronary Disea
Disease and Changes in Risk Factors in Various Stu
Note that the same IMPACT model shows more of the decrease in deaths in the U
compared with Scotland (line 5), England and Wales (line 6), and Finland (line 10)uires coordination among first responders, emergency de- rartments, and cardiac catheterization laboratories. A state-
ide program (RACE [Reperfusion of Acute Myocardial
nfarction in North Carolina Emergency Departments]) in
orth Carolina to provide rapid access to reperfusion
herapy for ST-segment elevation MI patients reduced
reatment delays in both percutaneous coronary intervention
apable and nonpercutaneous coronary intervention hospi-
als (24). A new citywide protocol in Ottawa reduced
oor-to-balloon times for primary angioplasty (25), and
atients who had an electrocardiogram performed in the
eld by paramedics were referred directly to a center capable
f performing primary angioplasty and had significantly less
elay in all measures of care delivery, including receipt of an
lectrocardiogram, arrival at a cardiac center, and the initial
alloon inflation. A protocol mandating emergency depart-
ent activation of the catheterization laboratory and imme-
iate patient transfer if the laboratory was not available
educed door-to-balloon time by 38 min (26) and increased
reatment within 90 min from 28% to 71%. The rapid
ctivation of treatment systems for acute MI may, however,
ead to angiography in some patients who are not having an
cute MI. Roughly 10% of 1,335 patients at a regional
e to Treatments for Established
(Citations in the Original Article)
e 8) are due to treatment
inted, with permission, from Ford et al. (14).se Du
dies
.S. (lin
. Repreferral center in Minneapolis went to the catheterization
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Year in Epidemiology, HSR, and Outcomes Research April 21, 2009:1459–66aboratory but had no coronary disease, negative cardiac
arkers, or both (27).
Hospitals use specialized code teams to respond rapidly to
npatients who experience a cardiac arrest. Two recent
tudies showed that response to and outcomes of cardiac
rrests during nights and weekends were significantly worse
han during the day (28,29). In a study of 6,789 patients at
69 hospitals, after-hours defibrillation was significantly
elayed (28). In a larger study of 58,593 cases of cardiac
rrest in 507 hospitals (29), survival to hospital discharge
as significantly lower for cardiac arrests that occurred at
ight (14.7%) than during the day (19.8%).
Optimal use of tests at the time of initial diagnosis and in
ubsequent monitoring of patients over the course of their
isease has not been established. The value of measuring
rain natriuretic peptide (BNP) levels in patients with heart
ailure was tested in 2 randomized trials (30,31). In the
MPROVE-CHF (Improved Management of Patients
ith Congestive Heart Failure) study, 500 patients pre-
enting to 1 of 7 emergency departments in Canada were
andomized to have NT-proBNP results used to guide
anagement or to be managed conventionally. The patients
andomized to NT-proBNP assessment had shorter stays in
he emergency department, fewer subsequent rehospitaliza-
ions within 60 days, and lower total costs of care (30). In
he STARS-BNP (Systolic Heart Failure Treatment Sup-
orted by BNP) trial, 220 outpatients with stable heart
ailure were randomized to BNP monitoring with a goal of
owering plasma levels 100 pg/ml or to conventional
linical monitoring (31). During the subsequent follow-up,
he 110 patients randomized to BNP-guided therapy had
ignificantly more medication adjustments, greater drug
Figure 2 Cost Acceptability Curve for Abdominal
Aortic Aneurysm Screening With Ultrasonography
The vertical axis is the cumulative percentage of simulations in which the
cost-effectiveness ratio was below the value shown on the horizontal axis. The
best estimate of the cost-effectiveness ratio ($19,500 per life-year added) is in
the middle of this curve. Reprinted, with permission, from Kim et al. (16).oses, and were hospitalized for heart failure at one-half the fate of the conventionally managed patients. Serial assess-
ent of the health status of patients with congestive heart
ailure also provides information on their subsequent risk
f death, as a drop of 5 points in the Kansas City
ardiomyopathy Questionnaire was correlated with a
0% increase in subsequent mortality (32).
ealth Policy
ay-for-performance (P4P) is a new buzzword that refers to
arious programs by which payors provide financial incen-
ives to doctors or hospitals based on whether they meet a
et of benchmarks in the provision of care. Although the
oal of P4P is to improve quality of care, a pilot project did
ot have a significant impact on evidence-based medication
se for acute MI in participating hospitals (33). Another
tudy suggested a hospital P4P program had a modest effect
34). Primary care doctors in the United Kingdom improved
he quality of care for diabetes but not for coronary disease
fter the introduction of P4P (35). Like any intervention,
4P may have unintended consequences. Karve et al. (36)
sed Medicare data to rank hospitals on care measures for
cute MI, heart failure, and pneumonia. They found hos-
itals that care for more African-American patients were
ess often eligible for bonuses and more likely to face
nancial penalties under a P4P plan. Physician P4P in
ondon had less impact on minority patients with diabetes
han on white patients (37). These studies suggest that P4P
rograms will need to be assessed carefully to determine the
ptimal form of the intervention itself, as well as to assess
he clinical outcomes of the intervention on quality of care,
ccess, and health disparities.
Measuring performance accurately is clearly essential for
he success of P4P programs, but how should performance
e measured? O’Brien et al. (38) showed that the ranking of
ospitals on coronary artery bypass surgery was quite dif-
erent depending on whether performance was assessed
sing a set of process measures or by outcome measures.
heir results suggest that a careful approach to defining
erformance will be essential.
The affordability of prescription drugs was a major reason
or the recent enactment of a pharmacy benefit in Medicare.
houdhry et al. (39) assessed the likely costs and outcomes
f full drug coverage for medications prescribed after an
cute MI. They project that the drug benefit should increase
dherence to evidence-based therapies, which should in turn
mprove survival and reduce total medical costs by reducing
ubsequent hospitalization. In a study of changing coverage
olicies in British Columbia, introduction of either copay-
ents or coinsurance for prescription medications doubled
he chance a patient would stop taking statin therapy (40).
n a review of published evidence, Goldman et al. (41)
eport that every 10% increase in cost sharing decreases
rescription drug use by 2% to 6%.
The increase in health care costs has been driven by manyactors, but the introduction of new medical technology has
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April 21, 2009:1459–66 Year in Epidemiology, HSR, and Outcomes Researcheen identified as a major contributor. Medical imaging has
rawn the particular interest of health care policymakers
ecause of its particularly rapid growth. Pearlman et al. (42)
howed that echocardiography in Medicare beneficiaries
rew an average of 7.7% per year from 1999 to 2004, with
3-fold variation in per-capita echocardiography use across
tates.
Public reporting of hospital outcomes has been embraced
s a method to improve choice of providers, but criticized
or not adjusting fully the severity of illness among patients.
tukenborg et al. (43) showed that risk adjustment for acute
I was improved by the availability of International Clas-
ification of Diseases-9th Edition codes that distinguish
onditions present on hospital admission from complica-
ions that subsequently developed in-hospital. Acute non-
ardiac conditions present on admission were found to
ncrease in-hospital mortality for acute MI significantly
44). The use of invasive treatment for cardiogenic shock
fter acute MI was significantly lower in New York State,
here operator specific mortality for angioplasty and bypass
urgery is publicly reported, than in other states (45), which
uggests that physicians in New York State may avoid
reating high-risk patients based on concerns about a
egative effect on their reported procedural outcomes.
utcomes Research
bservational studies of the outcomes of clinical manage-
ent decisions can provide important insights into optimal
herapies, despite the lack of randomization. One interest-
ng example from the Cleveland Clinic examined whether a
onger “shelf-life” of stored red blood cells affected the
utcomes of coronary bypass surgery (46). Patients who
eceived blood stored more than 14 days had more compli-
ations (26% vs. 22%, p  0.001) and significantly greater
isk-adjusted mortality in-hospital and during the subse-
uent year. A large registry of patients undergoing bypass
urgery (47) reported that preoperative anemia was associ-
ted with a 2-fold increase in death, stroke, or renal failure
fter adjusting for confounding factors. Another, multi-
enter study found that preoperative anemia increased
ardiac events after bypass surgery, primarily in those with
omorbidities (48). These studies underscore the difficulties
urrounding the management of anemia and transfusions in
cutely ill patients.
If anemia is bad and transfusions not good either, perhaps
eduction of bleeding during bypass surgery would be a
ational approach to improving outcome. The antifibrino-
ytic agent aprotinin reduces bleeding during cardiac sur-
ery, but observational studies of 9,875 patients in the
ristol Royal Infirmary (49), 10,275 patients at Duke
edical Center (50), and 78,199 patients in the Premier
erspective Cardiovascular Database (51) all showed signif-
cantly worse outcomes after aprotinin treatment. These
bservational results were consistent with the results of the
andomized BART (Blood Conservation Using Antifi- mrinolytics in a Randomized Trial) of 2,331 high-risk
atients, in which aprotinin increased mortality by 53%
ompared with 2 other antifibrinolytic agents (52), despite
ower rates of bleeding. On the basis of these data, aprotinin
as been withdrawn from the market.
Treatment options for abdominal aortic aneurysm now
nclude open surgical repair and endovascular repair. Small
andomized trials suggested endovascular repair had good
hort-term results, but larger studies with long-term out-
omes have been needed. Schermerhorn et al. (53) used
edicare data from 45,660 patients to perform an observa-
ional, nonrandomized comparison of these alternatives
sing the technique of propensity score matching. Open
epair had a significantly higher procedural mortality (4.8%
s. 1.2%), but by 4 years of follow-up, the mortality of
atients who had either open or endovascular repair was
qual, roughly 30%.
Off- versus on-pump coronary artery bypass graft surgery
ere compared in an observational, nonrandomized study
y Hannan et al. (54) using the New York State Cardiac
urgery Registry based on matched pairs of patients with
quivalent propensity scores. During 3 years of follow-up,
he survival after off-pump surgery (89.4%) was not signif-
cantly different from that of on-pump surgery (90.1%), but
he rate of repeat revascularization was significantly higher
fter off-pump (10.1%) than on-pump surgery (6.4%).
hese investigators also used a propensity score approach to
ompare patients with multivessel disease treated either
ith coronary bypass surgery or coronary angioplasty in
ew York State (55). They found survival over an average
8 month follow-up was better after surgery than angio-
lasty, both in patients with 3-vessel disease (94.0% vs.
2.7%) and in patients with 2-vessel disease (96.0% vs.
4.6%).
In the absence of randomization, statistical methods must
e used to control for differences in patients given alterna-
ive therapies. Instrumental variables methods are a less
requently used tool that was developed by economists, and
lthough it has been used less often in medical studies than
he propensity score method, it may have advantages. Using
ata on Medicare patients with an acute MI, Stukel et al.
56) tested the effect of cardiac catheterization on mortality
sing three alternative statistical methods to adjust for
onrandom assignment of therapy. Although all 3 statistical
ethods showed lower risk-adjusted mortality with cathe-
erization, the treatment effect was 49% when estimated by
tandard direct risk adjustment methods, 46% when esti-
ated by propensity score methods, but only 16% when
stimated by instrumental variables methods, which was
loser to the risk reductions of 8% to 21% reported by
andomized trials (56). Pilote et al. (57) also used an
nstrumental variables method to assess the effect of coro-
ary angiography (and subsequent revascularization) on
-year mortality after acute MI. They found a significant
1% reduction in mortality related to use of invasive
anagement.
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Year in Epidemiology, HSR, and Outcomes Research April 21, 2009:1459–66Yet another approach to observational treatment assess-
ent is the time-varying exposure method, which is appli-
able to interventions applied over time, such as use of
rescription drugs. Ho et al. (58) applied this approach to
ssess the effects of clopidogrel after acute coronary syn-
romes and found a significantly greater risk of death and
I in the 90 days after stopping clopidogrel. Interestingly,
his effect was found in medically treated patients as well as
hose treated with angioplasty, suggesting there may be
rebound” in platelet aggregation after clopidogrel discon-
inuation.
ariations in Care
ariations in clinical practice according to characteristics of
he patient, the doctor, or the hospital have attracted
onsiderable attention because of the concern that they may
ompromise quality of care and clinical outcomes. Dispar-
ties in the use of invasive cardiac procedures according to
he patient’s race or sex have drawn particular scrutiny. Data
rom the Cooperative Cardiovascular Project from Medi-
are patients treated for acute MI showed African-
merican patients were significantly less likely to receive
imely reperfusion, a beta-blocker, coronary angiography,
ngioplasty, and bypass surgery than white patients, even
fter adjusting for differences in comorbidity (59). Although
frican-American patients may not have as ready access to
ospitals that perform cardiac procedures, Popescu et al.
60) found the lower invasive procedure use among African
mericans was evident both in hospitals with and without
nvasive procedure capability. Lucas et al. (61) found that
tress tests were also less likely to be used in African-
merican patients and in women. Minority patients may be
ess willing to travel to referral centers to undergo invasive
ardiac procedures, and Sketch et al. (62) showed that
utreach with a mobile catheterization laboratory that
isited local community hospitals led to significantly higher
rocedure use in African-American subjects and women.
Disparities in the use of implantable cardioverter-
efibrillators (ICDs) also have been demonstrated. Women
ere less than one-half as likely as men to have an ICD
mplanted for either primary or secondary prevention of
udden death in an analysis of Medicare data (63). In a
egistry of patients with heart failure, women eligible for
CD therapy were 40% less likely to receive an ICD
ompared with white men, and black men were 27% less
ikely to receive an ICD (64). These differences in ICD use
ere not explained by clinical measures.
Characteristics of the treating physician may also affect
atterns of care. Turchin et al. (65) analyzed the treatment
f 8,127 patients with hypertension and diabetes treated by
01 internists (65) and reported that physicians who had
een board certified for 10 years or less were significantly
ore likely to intensify antihypertensive drug treatment in
he face of an elevated blood pressure reading. In the
RUSADE (Can Rapid risk stratification of Unstablengina patients Suppress ADverse outcomes with Early
mplementation of the ACC/AHA Guidelines) registry
66), patients with acute coronary syndromes were signifi-
antly more likely to receive evidence-based therapies if care
as provided on a cardiology specialty service than on other
ypes of services. Patients with acute MI or heart failure
reated by hospitalists had shorter lengths of stay with
quivalent mortality than patients treated by general inter-
ists or family physicians (67).
Hospital and health system characteristics also may affect
rocesses of care. Shah et al. (68) analyzed care in the
RUSADE registry according to the ownership status of
he hospital and found generally similar use of evidence-
ased therapies in for-profit and not-for-profit facilities.
allamothu et al. (69) evaluated treatment and outcomes
or acute MI and heart failure among Medicare beneficiaries
reated in one of 16 cardiac specialty hospitals compared
ith 121 similar general hospitals. Patients seen at the
pecialty hospitals were younger, had less comorbidity, and
ad significantly lower 30-day mortality rates. The differ-
nce in mortality was attenuated, but not eliminated, by
djustment for potential confounding factors.
Geographic practice variation in the use of cardiac pro-
edures has been documented previously, but the reasons for
his variation have been unclear. The possibility that areas
ith high utilization have more inappropriate procedures
as examined by Ko et al. (70) among Medicare beneficia-
ies after acute MI. They found that catheterization was
6% higher for strong indications (Class I) and 40% greater
or equivocal indications (Class II) in regions with greater
verall use of angiography, but catheterization was also 34%
reater for inappropriate indications (Class III).
onclusions
pidemiology, HSR, and outcomes research are examples
f the value of multidisciplinary research as applied to
ardiovascular disease. Research in these fields typically
equires investigators from different backgrounds, high-
uality data from a variety of sources, statistical methods to
nalyze observational data, and often can be applied directly
o clinical practice.
Thus, population sciences research, only a portion of
hich we could summarize here, will continue to be
mportant in translating research discoveries into practice
nd improving the quality and outcomes of care for cardio-
ascular disease.
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